written on 11.06.2014

Allergan loses Latisse patent fight, jeopardizing up to $200M in sales


As Allergan tries to fend off Valeant's hostile advances, it's been touting its sales prospects as a standalone company. But with a Tuesday court ruling invalidating patents on its eyelash growth drug Latisse, its top-line potential could shrink a little down the line.